DE60133921D1 - Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie - Google Patents

Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie

Info

Publication number
DE60133921D1
DE60133921D1 DE60133921T DE60133921T DE60133921D1 DE 60133921 D1 DE60133921 D1 DE 60133921D1 DE 60133921 T DE60133921 T DE 60133921T DE 60133921 T DE60133921 T DE 60133921T DE 60133921 D1 DE60133921 D1 DE 60133921D1
Authority
DE
Germany
Prior art keywords
heterozygot
rosuvastatin
treatment
family hypercholesterolemia
hypercholesterolemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60133921T
Other languages
German (de)
English (en)
Inventor
Ali Raza
Howard Gerard Hutchinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60133921(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of DE60133921D1 publication Critical patent/DE60133921D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60133921T 2000-11-22 2001-11-16 Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie Expired - Lifetime DE60133921D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0028429.9A GB0028429D0 (en) 2000-11-22 2000-11-22 Therapy
PCT/GB2001/005041 WO2002041895A1 (en) 2000-11-22 2001-11-16 Use of rosuvastatin (zd-4522) in the treatment of heterozygous familial hypercholesterolemia

Publications (1)

Publication Number Publication Date
DE60133921D1 true DE60133921D1 (de) 2008-06-19

Family

ID=9903629

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60133921T Expired - Lifetime DE60133921D1 (de) 2000-11-22 2001-11-16 Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie

Country Status (34)

Country Link
US (1) US6858618B2 (OSRAM)
EP (1) EP1339409B1 (OSRAM)
JP (2) JP5062940B2 (OSRAM)
KR (1) KR100815042B1 (OSRAM)
CN (1) CN1268339C (OSRAM)
AR (1) AR031766A1 (OSRAM)
AT (1) ATE394103T1 (OSRAM)
AU (2) AU2002214165B9 (OSRAM)
BG (1) BG66009B1 (OSRAM)
BR (1) BR0115511A (OSRAM)
CA (1) CA2429263C (OSRAM)
CY (1) CY1110428T1 (OSRAM)
CZ (1) CZ301583B6 (OSRAM)
DE (1) DE60133921D1 (OSRAM)
DK (1) DK1339409T3 (OSRAM)
EE (1) EE05507B1 (OSRAM)
ES (1) ES2305118T3 (OSRAM)
GB (1) GB0028429D0 (OSRAM)
HU (1) HUP0301380A3 (OSRAM)
IL (2) IL155919A0 (OSRAM)
IS (1) IS6819A (OSRAM)
MX (1) MXPA03004336A (OSRAM)
MY (1) MY134902A (OSRAM)
NO (1) NO326245B1 (OSRAM)
NZ (1) NZ525754A (OSRAM)
PL (1) PL365386A1 (OSRAM)
PT (1) PT1339409E (OSRAM)
RU (1) RU2294744C2 (OSRAM)
SI (1) SI1339409T1 (OSRAM)
SK (1) SK6212003A3 (OSRAM)
TW (1) TWI238720B (OSRAM)
UA (1) UA75614C2 (OSRAM)
WO (1) WO2002041895A1 (OSRAM)
ZA (1) ZA200303636B (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003305D0 (en) * 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
EP1628685B1 (en) 2003-04-25 2010-12-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
MXPA05011296A (es) * 2003-04-25 2006-01-24 Gilead Sciences Inc Conjugados de fosfonato inhibidores de la cinasa.
WO2005023778A2 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US7432273B2 (en) * 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
US7777034B2 (en) 2003-11-24 2010-08-17 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
EP1689723B1 (en) * 2003-12-02 2011-04-27 Teva Pharmaceutical Industries, Ltd. Reference standard for characterization of rosuvastatin
US20070179166A1 (en) * 2003-12-24 2007-08-02 Valerie Niddam-Hildesheim Process for preparation of statins with high syn to anti ratio
US7851624B2 (en) * 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
US20060013861A1 (en) * 2004-05-26 2006-01-19 Kgk Synergize Inc. Functional foods comprising flavonoids and tocotrienols and methods thereof
EP1673351A1 (en) * 2004-07-13 2006-06-28 Teva Pharmaceutical Industries Ltd. A process for the preparation of rosuvastatin involving a tempo-mediated oxidation step
WO2006110157A2 (en) 2004-07-27 2006-10-19 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
CA2591439C (en) * 2005-02-22 2013-03-26 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US20070037979A1 (en) * 2005-02-22 2007-02-15 Valerie Niddam-Hildesheim Preparation of rosuvastatin
US20070167625A1 (en) * 2005-02-22 2007-07-19 Anna Balanov Preparation of rosuvastatin
MX2007004427A (es) * 2005-08-16 2007-06-14 Teva Pharma Intermedio de rosuvastatina cristalina.
US8383614B2 (en) * 2008-01-31 2013-02-26 The Trustees Of The University Of Pennsylvania Hypercholestrolemia and tendinous injuries
US9427437B2 (en) 2008-01-31 2016-08-30 The Trustees Of The University Of Pennsylvania Hypercholesterolemia and tendinous injuries
WO2009143776A1 (zh) 2008-05-27 2009-12-03 常州制药厂有限公司 瑞舒伐他汀钙盐的制备方法及其中间体
HRP20120700T1 (hr) 2008-07-08 2012-09-30 Gilead Sciences SOLI SPOJEVA INHIBITORA HIV-a
AR092872A1 (es) 2012-09-17 2015-05-06 Madrigal Pharmaceuticals Inc Metodo para sintetizar analogos de la hormona tiroidea y polimorfos de los mismos
US9132117B2 (en) 2013-06-17 2015-09-15 Kgk Synergize, Inc Compositions and methods for glycemic control of subjects with impaired fasting glucose
US10600502B2 (en) 2016-12-20 2020-03-24 Astrazeneca Uk Ltd. Systems and methods for dispensing a statin medication over the counter
ES2892402T3 (es) 2017-08-01 2022-02-04 Gilead Sciences Inc Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
PE20220164A1 (es) 2019-05-27 2022-01-28 Immatics Us Inc Vectores viricos y uso de los mismos en terapias celulares adoptivas
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
US20220008519A1 (en) 2020-07-09 2022-01-13 Costa Rican Social Security Fund / Caja Costarricense de Seguro Social (CCSS) Treatment of severe acute respiratory syndrome-related coronavirus infection with klotho
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
JP2024506848A (ja) * 2021-02-01 2024-02-15 マドリガル ファーマシューティカルズ インコーポレイテッド 肝障害又は脂質障害の治療のためのロスバスタチンとレスメチロムの治療的組み合わせ
US12377104B1 (en) 2024-02-06 2025-08-05 Madrigal Pharmaceuticals, Inc. Methods for treating a fatty liver disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2051907C1 (ru) * 1989-05-22 1996-01-10 Сандос АГ Способ получения 7-замещенной гептен-6-овой кислоты
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US6369103B1 (en) * 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
AU6294501A (en) * 2000-09-20 2002-04-02 Rtp Pharma Inc Spray drying process and compositions of fenofibrate

Also Published As

Publication number Publication date
AR031766A1 (es) 2003-10-01
ZA200303636B (en) 2004-08-12
BG107811A (bg) 2004-03-31
ATE394103T1 (de) 2008-05-15
EP1339409A1 (en) 2003-09-03
PT1339409E (pt) 2008-07-07
BG66009B1 (bg) 2010-10-29
NZ525754A (en) 2004-10-29
CY1110428T1 (el) 2015-04-29
NO20032292D0 (no) 2003-05-21
HUP0301380A3 (en) 2007-03-28
DK1339409T3 (da) 2008-09-08
HK1056691A1 (en) 2004-02-27
EE05507B1 (et) 2012-02-15
CN1630520A (zh) 2005-06-22
SK6212003A3 (en) 2003-11-04
CZ301583B6 (cs) 2010-04-21
IL155919A0 (en) 2003-12-23
CZ20031406A3 (cs) 2003-09-17
WO2002041895A1 (en) 2002-05-30
JP5062940B2 (ja) 2012-10-31
IS6819A (is) 2003-05-19
NO20032292L (no) 2003-07-17
GB0028429D0 (en) 2001-01-10
KR100815042B1 (ko) 2008-03-18
MY134902A (en) 2007-12-31
AU1416502A (en) 2002-06-03
AU2002214165B9 (en) 2013-07-04
EP1339409B1 (en) 2008-05-07
MXPA03004336A (es) 2003-08-19
UA75614C2 (uk) 2006-05-15
US6858618B2 (en) 2005-02-22
TWI238720B (en) 2005-09-01
JP2010031047A (ja) 2010-02-12
US20040072852A1 (en) 2004-04-15
HUP0301380A2 (hu) 2003-10-28
EE200300239A (et) 2003-08-15
BR0115511A (pt) 2003-12-30
KR20030048479A (ko) 2003-06-19
PL365386A1 (en) 2005-01-10
CN1268339C (zh) 2006-08-09
RU2294744C2 (ru) 2007-03-10
SI1339409T1 (sl) 2008-08-31
IL155919A (en) 2009-09-01
CA2429263C (en) 2009-03-17
ES2305118T3 (es) 2008-11-01
JP2004522714A (ja) 2004-07-29
AU2002214165B2 (en) 2006-12-14
NO326245B1 (no) 2008-10-27
CA2429263A1 (en) 2002-05-30

Similar Documents

Publication Publication Date Title
DE60133921D1 (de) Verwendung von rosuvastatin (zd-4522) zur behandlung von heterozygoter familiärer hypercholesterolämie
DE60033030D1 (de) Verwendung von gegen cd20 gerichteten antikörpern zur behandlung der graft versus host krankheit
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
ATE241986T1 (de) Verwendung von chinazolin verbindungen zur behandlung von polyzystischer nierenkrankheit
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE251903T1 (de) Verwendung von phosphororganischen verbindungen zur therapeutischen und prophylaktischen behandlung von infektionen
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE265860T1 (de) Impstoff zur behandlung von atherosclerosis
ATE451921T1 (de) Phenylindole zur behandlung von hiv
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE292134T1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DE50014041D1 (de) Verwendung von epinastin zur behandlung von allergischer rhinitis/konjunktivitis
DE60208186D1 (de) Chinazolin- und chinazolinähnliche verbindungen zur behandlung von integrinvermittelten erkrankungen
DE60030554T8 (de) Verwendungen von et743 zur behandlung von krebs
DE60030861D1 (de) Verwendung von escitalopram zur Behandlung von generalisierten Angstzuständen
DE60214355D1 (de) Exemestan zur behandlung von hormonabhängigen störungen
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE312104T1 (de) Verbindungen zur behandlung von beeinträchtigten fundischen entspannung
DE60233740D1 (de) Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen
ATE253578T1 (de) Oxazinochinolone zur behandlung von viralen infektionen

Legal Events

Date Code Title Description
8363 Opposition against the patent